Surrozen Provides Second Quarter 2024 Financial Results and Business Update
Surrozen (Nasdaq: SRZN) reported Q2 2024 financial results and business updates. Key highlights include:
- Ongoing enrollment in SZN-043 Phase 1b trial for Severe Alcoholic Hepatitis
- Presented first-in-human data from SZN-043 Phase 1a trial at EASL
- Published study on Targeted Protein Degradation technologies
- Cash position: $37.8 million as of June 30, 2024
- R&D expenses: $5.3 million, down from $6.9 million in Q2 2023
- Net loss: $25.3 million, up from $9.4 million in Q2 2023
The company anticipates proof-of-concept data from the SZN-043 Phase 1b trial in H1 2025 and potential nomination of a lead Fzd-4 targeted Wnt agonist development candidate in 2024, which could trigger a $10 million milestone payment from Boehringer Ingelheim.
Surrozen (Nasdaq: SRZN) ha riportato i risultati finanziari e gli aggiornamenti aziendali del secondo trimestre del 2024. I punti salienti includono:
- Immissione continua nello studio di fase 1b di SZN-043 per epatite alcolica severa
- Presentati dati di prima applicazione umana dallo studio di fase 1a di SZN-043 all'EASL
- Pubblicato uno studio sulle tecnologie di degradazione mirata delle proteine
- Posizione di cassa: 37,8 milioni di dollari al 30 giugno 2024
- Spese R&S: 5,3 milioni di dollari, in calo rispetto ai 6,9 milioni di dollari del secondo trimestre del 2023
- Perdita netta: 25,3 milioni di dollari, in aumento rispetto ai 9,4 milioni di dollari nel secondo trimestre del 2023
L'azienda prevede dati di prova del concetto dal trial di fase 1b di SZN-043 nella prima metà del 2025 e la possibile nomina di un candidato di sviluppo Fzd-4 mirato all'agonista Wnt nel 2024, il che potrebbe attivare un pagamento di 10 milioni di dollari come milestone da Boehringer Ingelheim.
Surrozen (Nasdaq: SRZN) informó sobre los resultados financieros y las actualizaciones comerciales del segundo trimestre de 2024. Los aspectos destacados incluyen:
- Inscripción en curso en el ensayo de fase 1b de SZN-043 para hepatitis alcohólica severa
- Presentados datos de primera aplicación en humanos del ensayo de fase 1a de SZN-043 en EASL
- Publicada un estudio sobre tecnologías de degradación de proteínas dirigida
- Posición de efectivo: 37,8 millones de dólares al 30 de junio de 2024
- Gastos en I+D: 5,3 millones de dólares, bajando de 6,9 millones de dólares en el segundo trimestre de 2023
- Pérdida neta: 25,3 millones de dólares, en aumento desde los 9,4 millones de dólares en el segundo trimestre de 2023
La empresa anticipa datos de prueba de concepto del ensayo de fase 1b de SZN-043 en la primera mitad de 2025 y la posible nominación de un candidato de desarrollo de agonistas Wnt dirigidos a Fzd-4 en 2024, lo que podría desencadenar un pago de 10 millones de dólares como hito por parte de Boehringer Ingelheim.
Surrozen (Nasdaq: SRZN)은 2024년 2분기 재무 결과 및 사업 업데이트를 보고했습니다. 주요 내용은 다음과 같습니다:
- 심각한 알코올성 간염을 위한 SZN-043 1b 단계 시험에 지속적으로 등록 중
- EASL에서 SZN-043 1a 단계 시험의 최초 인간 데이터 발표
- 표적 단백질 분해 기술에 대한 연구 발표
- 현금 보유: 2024년 6월 30일 기준 3,780만 달러
- 연구개발 비용: 530만 달러, 2023년 2분기 690만 달러에서 감소
- 순 손실: 2,530만 달러, 2023년 2분기 940만 달러에서 증가
회사는 SZN-043 1b 단계 시험의 개념 증명 데이터를 2025년 상반기에 예상하며, 2024년에 Fzd-4에 대한 표적 Wnt 작용제 개발 후보를 추천할 가능성이 있으며, 이는 Boehringer Ingelheim로부터 1,000만 달러의 이정표 지급trigger할 수 있습니다.
Surrozen (Nasdaq: SRZN) a annoncé les résultats financiers et les mises à jour commerciales du deuxième trimestre 2024. Les points clés incluent :
- Inscription en cours dans l'essai de phase 1b de SZN-043 pour hépatite alcoolique sévère
- Données de première application chez l'homme de l'essai de phase 1a de SZN-043 présentées à l'EASL
- Étude publiée sur les technologies de dégradation ciblée des protéines
- Position de trésorerie : 37,8 millions de dollars au 30 juin 2024
- Dépenses R&D : 5,3 millions de dollars, en baisse par rapport à 6,9 millions de dollars au deuxième trimestre 2023
- Perte nette : 25,3 millions de dollars, en hausse par rapport à 9,4 millions de dollars au deuxième trimestre 2023
L'entreprise anticipe des données de preuve de concept de l'essai de phase 1b de SZN-043 au premier semestre 2025 et la nomination potentielle d'un candidat au développement d'agonistes Wnt ciblés Fzd-4 en 2024, ce qui pourrait déclencher un paiement de 10 millions de dollars de Boehringer Ingelheim.
Surrozen (Nasdaq: SRZN) berichtete über die finanziellen Ergebnisse und Geschäftsupdates für das zweite Quartal 2024. Die wichtigsten Highlights sind:
- Fortlaufende Rekrutierung in die Phase-1b-Studie von SZN-043 für schwere alkoholische Hepatitis
- Vorstellung von Daten aus der ersten humanen Studie von SZN-043 Phase 1a bei der EASL
- Veröffentlichung einer Studie zu gezielter Proteinabbau Techniken
- Cash-Position: 37,8 Millionen USD zum 30. Juni 2024
- F&E-Ausgaben: 5,3 Millionen USD, Rückgang von 6,9 Millionen USD im 2. Quartal 2023
- Nettoverlust: 25,3 Millionen USD, gestiegen von 9,4 Millionen USD im 2. Quartal 2023
Das Unternehmen erwartet Daten zur Machbarkeit aus der SZN-043 Phase-1b-Studie im ersten Halbjahr 2025 und die potenzielle Nominierung eines führenden Fzd-4 gezielten Wnt Agonisten-Entwicklungskandidaten im Jahr 2024, was eine Meilensteinzahlung von 10 Millionen USD von Boehringer Ingelheim auslösen könnte.
- Enrollment ongoing in SZN-043 Phase 1b trial for Severe Alcoholic Hepatitis
- Presented first-in-human data from SZN-043 Phase 1a trial at EASL
- Published study demonstrating application of Targeted Protein Degradation technologies
- Cash position increased to $37.8 million from $27.3 million in Q1 2024
- R&D expenses decreased to $5.3 million from $6.9 million in Q2 2023
- Potential $10 million milestone payment from Boehringer Ingelheim partnership in 2024
- Net loss increased to $25.3 million from $9.4 million in Q2 2023
- Loss on issuance of common stock, pre-funded warrants and warrants of $20.4 million in Q2 2024
- Decrease in interest income due to lower money market funds and marketable securities
Insights
The Q2 2024 results for Surrozen paint a mixed financial picture. While the company's cash position improved to
Surrozen's progress in its SZN-043 program for severe liver disease is noteworthy. The initiation of the Phase 1b trial and the presentation of Phase 1a results at EASL demonstrate forward momentum. The safety and tolerability profile in healthy volunteers and cirrhosis patients, along with evidence of target engagement, are positive indicators. However, the true test will be the proof-of-concept data expected in H1 2025. The publication in eLife showcasing new ASGR bispecific antibodies with enhanced Wnt-signaling is intriguing, potentially expanding the company's therapeutic reach in liver diseases. While promising, it's important to remember that early-stage research often faces challenges in clinical translation.
Surrozen's focus on the Wnt pathway for tissue repair and regeneration positions it in a niche but potentially lucrative market. The partnership with Boehringer Ingelheim for retinal diseases adds credibility and potential future revenue streams. However, the company faces significant challenges. The widened net loss and reliance on milestone payments highlight financial vulnerabilities. The
Enrollment ongoing in SZN-043 Phase 1b trial in patients with Severe Alcoholic Hepatitis
Presented first-in-human data from SZN-043 Phase 1a trial at EASL
Published study that demonstrated application of unique Targeted Protein Degradation technologies resulting in robust Wnt signal activation in bispecific antibodies based on the Company's SWEETS technology platform
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided second quarter 2024 financial results and business updates.
“We made significant progress in the second quarter with accomplishment of key milestones including dosing the first patient in the SZN-043 Phase 1b trial, presenting first-in-human data from the SZN-043 Phase 1a trial at EASL and publishing new information regarding the promise of our proprietary SWEETS platform,” said Craig Parker, President and Chief Executive Officer of Surrozen. “Surrozen is focused on transforming the treatment of severe diseases of the liver and eye, and we look forward to proof-of-concept data from the SZN-043 Phase 1b clinical trial in the first half of 2025.”
Research and Development Pipeline Highlights
SZN-043
Surrozen is developing SZN-043 for severe liver disease with an initial focus in severe alcohol-associated hepatitis.
Clinical Development Milestones and Medical Meeting Presentation
- Enrollment initiated and ongoing in Phase 1b trial; proof-of-concept data is anticipated in the first half of 2025
- Presented Phase 1a trial results at 2024 European Association for the Study of the Liver (EASL) in June 2024 (LINK: HERE)
- Treatment with SZN-043 was safe and well tolerated in healthy volunteers and patients with a history of liver cirrhosis
- Results demonstrated evidence of target engagement and Wnt-pathway mediated pharmacodynamic effects in the liver
Research Programs Publications
- Surrozen published study in eLife (LINK: HERE) describing development of two new ASGR bispecific antibodies that resulted in a robust and cell specific boost to Wnt-signaling through protein degradation technologies
- These ASGR-targeted SWEETS (Surrozen Wnt Signal Enhancer Engineered for Tissue Specificity) molecules represent a unique targeted protein degradation (TPD) platform, that functions via multiple mechanisms, and expands the potential opportunities to treat liver diseases through cell or tissue-specific regenerative therapeutics with enhanced Wnt signal activation
- Surrozen published a review article in iScience (LINK: HERE) that provided a comprehensive summary of work done in the field on invention of various Wnt activating platforms and highlighted the rationales and design rules described so far in this emerging field including the potential for Wnt agonists in the treatment of numerous tissue degenerative diseases
Corporate Updates
Corporate Partnerships
Surrozen executed a partnership with Boehringer Ingelheim (BI) in the fourth quarter of 2022 to develop a Wnt agonist, SZN-413, for the treatment of people with retinal diseases. We anticipate the potential to nominate the lead Fzd-4 targeted Wnt agonist development candidate in 2024, which would trigger a
Financial Results for the Second Quarter Ended June 30, 2024
Cash Position: Cash and cash equivalents were
Research and Development Expenses: Research and development expenses for the second quarter ended June 30, 2024 were
General and Administrative Expenses: General and administrative expenses for the second quarter ended June 30, 2024 were
Interest Income: Interest income for the second quarter ended June 30, 2024 was
Other Income, Net: Other income, net for the second quarter ended June 30, 2024 was
Loss on Issuance of Common Stock, Pre-Funded Warrants and Warrants: Loss on issuance of common stock, pre-funded warrants and warrants for the second quarter ended June 30, 2024 was
Net Loss: Net loss for the second quarter ended June 30, 2024 was
About SZN-043 for Severe Alcohol-Associated Hepatitis
SZN-043 is the first development candidate using Surrozen’s SWEETS™ technology. Surrozen is developing SZN-043 for severe liver diseases, initially focusing on alcohol-associated hepatitis. The Company has completed a Phase 1a clinical trial in patients with chronic liver disease and healthy volunteers. SZN-043 demonstrated acceptable safety and tolerability in all subjects, with evidence of target engagement, Wnt signal activation and effects on liver function. Enrollment is ongoing in the Phase 1b clinical trial in patients with severe alcohol-associated hepatitis and proof-of-concept data from this trial is anticipated in the first half of 2025.
About SZN-413 for Retinal Diseases
SZN-413 is a bi-specific antibody targeting Fzd4-mediated Wnt signaling designed using Surrozen’s SWAP™ technology. SZN-413 is being developed for the treatment of retinal vascular-associated diseases. Data generated by Surrozen with SZN-413 in preclinical models of retinopathy demonstrated that SZN-413 could potently stimulate Wnt signaling in the eye, induce normal retinal vessel regrowth, suppress pathological vessel growth and reduce vascular leakage. This novel approach could thus potentially allow for regeneration of healthy eye tissue, not only halting retinopathy, but possibly allowing for a full reversal of the patient’s disease.
In the fourth quarter of 2022, Surrozen entered into a strategic partnership with Boehringer Ingelheim for the research and development of SZN-413 for the treatment of retinal diseases. Under the terms of the agreement, Boehringer Ingelheim received an exclusive, worldwide license to develop SZN-413 and other Fzd4-specific Wnt-modulating molecules for all purposes, including as a treatment for retinal diseases, in exchange for an upfront payment to Surrozen of
About Wnt Signaling
Wnt signaling plays key roles in the control of development, homeostasis, and regeneration of many essential organs and tissues, including liver, intestine, lung, kidney, retina, central nervous system, cochlea, bone, and others. Modulation of Wnt signaling pathways has potential for treatment of degenerative diseases and tissue injuries. Surrozen’s platform and proprietary technologies have the potential to overcome the limitations in pursuing the Wnt pathway as a therapeutic strategy.
About Surrozen
Surrozen is a clinical stage biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a current focus on severe liver and eye diseases. For more information, please visit www.surrozen.com.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen’s discovery, research and development activities, in particular its development plans for its product candidates SZN-043 and SZN-413 (including anticipated clinical development plans and timelines, the availability of data, the potential for such product candidates to be used to treat human disease, as well as the potential benefits of such product candidates), and the Company’s partnership with Boehringer Ingelheim, including the potential for future success-based development, regulatory, and commercial milestone payments, in addition to mid-single digit to low-double digit royalties on sales. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical and clinical trials with respect to SZN-043, SZN-413 and potential future drug candidates; the Company’s ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen’s ability to identify, develop and commercialize drug candidates; Surrozen’s ability to successfully complete preclinical and clinical studies for SZN-043, SZN-413, or other future product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions; and all other factors discussed in Surrozen’s Annual Report on Form 10-K for the year ended December 31, 2023 and Surrozen’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 to be filed with the Securities and Exchange Commission (“SEC”) under the heading “Risk Factors,” and other documents Surrozen has filed, or will file, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen’s expectations, plans, or forecasts of future events and views as of the date of this press release. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen’s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor and Media Contact:
Investorinfo@surrozen.com
SURROZEN, INC. Condensed Consolidated Statements of Operations (In thousands, except per share amounts) (Unaudited) | ||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | $ | 5,335 | $ | 6,937 | $ | 10,582 | $ | 15,023 | ||||||||
General and administrative | 3,714 | 3,338 | 7,597 | 8,637 | ||||||||||||
Restructuring | — | — | — | 1,207 | ||||||||||||
Total operating expenses | 9,049 | 10,275 | 18,179 | 24,867 | ||||||||||||
Loss from operations | (9,049 | ) | (10,275 | ) | (18,179 | ) | (24,867 | ) | ||||||||
Interest income | 490 | 623 | 875 | 1,170 | ||||||||||||
Other income, net | 3,695 | 265 | 3,610 | 13 | ||||||||||||
Loss on issuance of common stock, pre-funded warrants and warrants | (20,397 | ) | — | (20,397 | ) | — | ||||||||||
Net loss | $ | (25,261 | ) | $ | (9,387 | ) | $ | (34,091 | ) | $ | (23,684 | ) | ||||
Net loss per share attributable to common stockholders, basic and diluted | $ | (7.99 | ) | $ | (4.68 | ) | $ | (13.00 | ) | $ | (11.84 | ) | ||||
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 3,162 | 2,004 | 2,622 | 2,001 |
SURROZEN, INC. Condensed Consolidated Balance Sheets (In thousands) | ||||||||
June 30, | December 31, | |||||||
2024 | 2023(1) | |||||||
(Unaudited) | ||||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 37,765 | $ | 36,043 | ||||
Accounts receivable | 2,112 | 2,152 | ||||||
Prepaid expenses and other current assets | 1,760 | 2,937 | ||||||
Total current assets | 41,637 | 41,132 | ||||||
Property and equipment, net | 1,198 | 1,969 | ||||||
Operating lease right-of-use assets | 1,175 | 1,889 | ||||||
Restricted cash | 688 | 688 | ||||||
Other assets | 373 | 402 | ||||||
Total assets | $ | 45,071 | $ | 46,080 | ||||
Liabilities and stockholders’ equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 173 | $ | 525 | ||||
Accrued and other liabilities | 3,644 | 4,126 | ||||||
Lease liabilities, current portion | 2,166 | 2,497 | ||||||
Total current liabilities | 5,983 | 7,148 | ||||||
Lease liabilities, noncurrent portion | — | 882 | ||||||
Warrant liabilities | 33,026 | 115 | ||||||
Total liabilities | 39,009 | 8,145 | ||||||
Stockholders’ equity: | ||||||||
Preferred stock | — | — | ||||||
Common stock | — | — | ||||||
Additional paid-in-capital | 261,848 | 259,630 | ||||||
Accumulated deficit | (255,786 | ) | (221,695 | ) | ||||
Total stockholders’ equity | 6,062 | 37,935 | ||||||
Total liabilities and stockholders’ equity | $ | 45,071 | $ | 46,080 |
(1) Derived from the audited financial statements, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
FAQ
What were Surrozen's (SRZN) key financial results for Q2 2024?
What is the status of Surrozen's (SRZN) SZN-043 clinical trials?
What potential milestone payment could Surrozen (SRZN) receive in 2024?